欢迎访问西安瑞禧生物技术有限公司官方网站

图片名

全国订购热线:
18966759382

首页 > 新闻资讯 > 市场活动

市场活动
行业新闻 市场活动 技术资讯

Molnupiravir-d7,EIDD-2801-d7; MK-4482-d7「同位素标记抑制剂」

作者:瑞禧生物 发布时间:2025-06-16 09:13:53 次浏览

生物活性:Molnupiravir-d7 is the deuterium labeled Molnupiravir. Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].
体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被掺入药物分子中,主要用作药物开发过程中定量的示踪剂。氘代因其可能影响药物的药代动力学和代谢特征而受到关注[3]。
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Molnupiravir-d7 相关抗体:
Poliovirus Receptor Antibody (YA2556)
分子量:336.35
Formula:C13H12D7N3O7
非标记 CAS:2492423-29-5
性状:固体
颜色:White to off-white
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Powder:-20°C:3 years,4°C:2 years
In solvent:-80°C:6 months,-20°C:1 month